Credit Suisse AG increased its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 101.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,400 shares of the company’s stock after buying an additional 77,859 shares during the period. Credit Suisse AG’s holdings in Meridian Bioscience were worth $2,130,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Louisiana State Employees Retirement System raised its stake in shares of Meridian Bioscience by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock valued at $237,000 after buying an additional 300 shares during the period. Arizona State Retirement System raised its stake in shares of Meridian Bioscience by 1.4% in the first quarter. Arizona State Retirement System now owns 21,941 shares of the company’s stock valued at $303,000 after buying an additional 300 shares during the period. RiverPoint Capital Management LLC raised its stake in shares of Meridian Bioscience by 2.9% in the first quarter. RiverPoint Capital Management LLC now owns 20,965 shares of the company’s stock valued at $289,000 after buying an additional 599 shares during the period. Mason Street Advisors LLC raised its stake in shares of Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock valued at $136,000 after buying an additional 667 shares during the period. Finally, Thrivent Financial For Lutherans raised its stake in shares of Meridian Bioscience by 3.9% in the first quarter. Thrivent Financial For Lutherans now owns 23,640 shares of the company’s stock valued at $326,000 after buying an additional 890 shares during the period. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Shares of Meridian Bioscience Inc. (NASDAQ VIVO) traded up 0.916% during mid-day trading on Tuesday, reaching $13.775. 18,253 shares of the company traded hands. The stock has a market capitalization of $581.33 million, a price-to-earnings ratio of 27.550 and a beta of 0.89. Meridian Bioscience Inc. has a 52-week low of $10.75 and a 52-week high of $19.85. The company’s 50 day moving average is $15.21 and its 200 day moving average is $14.12.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period last year, the company earned $0.21 EPS. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. On average, equities analysts forecast that Meridian Bioscience Inc. will post $0.67 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 17th. Shareholders of record on Monday, August 7th will be paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 3.66%. The ex-dividend date is Thursday, August 3rd. Meridian Bioscience’s payout ratio is 98.04%.

COPYRIGHT VIOLATION WARNING: “Meridian Bioscience Inc. (NASDAQ:VIVO) Shares Bought by Credit Suisse AG” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/08/meridian-bioscience-inc-nasdaqvivo-shares-bought-by-credit-suisse-ag.html.

Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Finally, Canaccord Genuity boosted their price objective on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Meridian Bioscience has an average rating of “Hold” and an average price target of $14.75.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.